Third (and this is crucial), I explore why youre considering this
Limitations of Current Research Transparency about what we don't know is as important as summarizing what we do know: No FDA approval: CJC-1295 hasn't completed the FDA approval process for any indication
Many spontaneously disappear later in adult life
As with all GLP-1 therapies, there are important safety considerations: Not suitable for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) May cause nausea, vomiting, diarrhea , especially during dose titration Monitor for signs of pancreatitis , gallbladder issues, or allergic reactions Not indicated for patients with Type 1 diabetes or those with severe gastrointestinal disorders Regular follow-ups, lab monitoring, and dose adjustments are part of the DrWell Methodology to ensure safe, effective outcomes
(2011) J Physiol
The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients
